Epidemiology and control of monkeypox outbreak in Houston,Texas  

作　　者：Abisola M.Oladimeji Abayomi Joseph Afe Louis Carillo Courtney Hundley Yufang Zhang Stephen Long Kirstin Short Roger Sealy Janeana White David Persse 

机构地区：[1]Bureau of Epidemiology,Houston Health Department,Houston,TX 77054,USA

出　　处：《Global Health Journal》2024年第3期133-139,共7页全球健康杂志（英文）

基　　金：supported by U.S.Centers for Disease Control and Prevention Public Health Crisis Response Funding titled CDC-RFA-TP22-2201:Public Health Crisis Response Cooperative Agreement.

摘　　要：Background:In the 2022-2023 global outbreak,the United States and state of Texas recorded a total of 31,277 and 3,085 confirmed monkeypox(Mpox)cases respectively as of November 2023.This study aims to investigate the demographic characteristics and risk factors of Mpox outbreak in Houston and document the epidemiologic control measures implemented with their outcomes.Methods:Houston Health Department received reports of suspected Mpox cases via electronic case reports and laboratory reports from healthcare providers within Houston.These were then investigated and reclassified as either positive or negative using DNA polymerase chain reaction tests.All the reported cases received between May 2022 and January 2023 were included in this study using convenient sampling methods.Descriptive statistics using frequency distribution was used to analyze the sociodemographic,clinical features and travel history of the cases.A two-sided Chi-squared test was used to determine association between Mpox test results and risk factors with significant level set at P<0.05.Other infection control measures such as community engagement,health education,tracking and contact tracing,vaccination,referrals and laboratory sample logistics support were implemented by the health department.Results:Out of the total of 1,625 suspected persons investigated for Mpox,724(44.6%)tested positive.Among the 724 confirmed cases,male was 700(96.7%),females 20(2.8%),transgender male 1(0.1%),transgender female 3(0.4%).Age groups 30-39 years constituted 43.6%,18-29 years 27.4%,40-49 years 18.2%,50-59 years was 8%.Race distribution of positive cases was Whites 43.4%,African American 38.7%,Asian 1.4%.Risk factors with P<0.05 included male gender,age groups 30-39 years and 40-49 years,travel history to Mpox endemic areas,recent sexual contact with known or suspected Mpox cases,human immunodeficiency virus seropositivity.Identifying as gay and bisexual were also statistically significant risk factors for Mpox infection.Conclusion:The timely implementation of p

关 键 词：MONKEYPOX Mpox RISKFACTORS Control Tecovirimat VACCINATION 

分 类 号：R51[医药卫生—内科学]